GENOVIOR and MNR Therapeutics announce an non-exclusive agreement for the commercialization of Fulvestrant in the Gulf Cooperation Council (GCC) region.
MNR Therapeutic, a Switzerland company focused on high-quality pharmaceutical solutions, and GENOVIOR Biotech, the key subsidiary for Polaris Group (TWSE:6550) listed on the Taiwan Stock Exchange, today announced that they have signed an non-exclusive agreement for the distribution and commercialization of Fulvestrant in the Gulf Cooperation Council (GCC) countries.
Fulvestrant is an established endocrine therapy used in the treatment of hormone receptor positive (HR+) / HER2-negative advanced breast cancer in postmenopausal women. It is recognized in international clinical practice and continues to represent a standard therapeutic option, including as a backbone in combination strategies with targeted therapies in appropriate patient populations.
The agreement covers registration, supply and market access activities across the GCC region. The collaboration aims to expand the availability of Fulvestrant in oncology centers where treatment access and continuity of supply are increasingly relevant to clinical practice.
Dr.Nicola Travierso, CEO of MNR therapeutics commented:
“This partnership reflects our commitment to supporting oncology care with reliable, high-quality therapeutic solutions. The GCC region has a clear clinical need for consistent access to endocrine therapies, and Fulvestrant remains an important component of treatment strategies for patients with HR+/HER2- advanced breast cancer.”
Dr. Steve Hsu, Chairman of Polaris Group and Genovior Biotech Corporation added:
“We are pleased to work with a partner experienced in market access and hospital channels across the GCC. This collaboration strengthens our regional presence and supports physicians and patients with a recognized and validated therapeutic option.”
The companies will begin the registration and market access process in coordination with regulatory authorities across GCC member states.
About Genovior Biotech Corporation
Genovior is an innovative pharmaceutical company specializing in the development of peptide active pharmaceutical ingredients (APIs) and formulations. Leveraging its proprietary fully synthetic peptide technology platform and sterile injectable formulation process, Genovior is committed to providing high-quality, highly stable, and internationally compliant pharmaceuticals and contract manufacturing services. Genovior ‘s products and services cover a wide range of therapeutic areas, including hypoglycemics, weight management, oncology, psychiatry, and critical care. Genovior has successfully expanded its product offerings into the European and Asian markets and continues to advance its global presence and internationalize its brand through strategic partnerships, drug licensing, and contract development and manufacturing.